Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals

International Archives of Allergy and Immunology

Volumn 116, Issue 3, 1998, Pages 228-239

  Zangerle, Robert ^a   Steinhuber, Sabine ^b   Sarcletti, Mario ^a   Dierich, Manfred P ^b   Wachter, Helmut ^b   Fuchs, Dietmar ^b   Möst, Johannes ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Disease progression; HIV; Immune activation; Viral load

Indexed keywords

BETA 2 MICROGLOBULIN; CD4 ANTIGEN; NEOPTERIN; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; ANTIGENS, CD; BETA 2-MICROGLOBULIN; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEOPTERIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, VIRAL;

EID: 0031873061     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023949     Document Type: Article

References (54)

1. Veugelers PJ, Schechter MT, Tindall B, et al: Differences in time from HIV seroconversion to CD4+ lymphocyte end-points and AIDS in cohorts of homosexual men. AIDS 1993;7: 1325-1329.
2. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD: Long-term HIV-1 infection without immunologic progression. AIDS 1994;8:1123-1128.
3. Rosenberg PS, Goederet JJ, Biggar RJ: Effect of age at seroconversion on the natural AIDS incubation distribution. Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters. AIDS 1994;8:803-810.
4. Corey L, Coombs RW: The natural history of HIV-1 infection: Implications for the assessment of antiretroviral therapy. Clin Infect Dis 1993:16(suppl 1):S2-S6.
5. Selwyn PA, Alcabes P, Hartel D, et al: Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992; 327:1697-1703.
6. Katz MH, Greenspan D, Westerhouse J, et al: Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS 1992;6:95-100.
7. Fahey JL, Taylor JM, Detels R, et al: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-172.
8. Moss AR, Bacchetti P, Osmond D, et al: Seropositivity for HIV-1 and the development of AIDS or AIDS related condition: Three year follow up of the San Francisco General Hospital cohort. BMJ 1988;296:745-750.
9. Phillips AN, Lee CA, Elford J, et al: p24 antigenaemia. CD4 lymphocyte counts and the development of AIDS. AIDS 1991;5:1217-1222.
10. Stein DS, Dorvick JA, Vermund SH: CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review. J Infect Dis 1992;165: 352-363.
11. Blatt SP, Hendrix CW, Butzin CH, et al: Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993;119:177-184.
12. 2-microglobulin and prediction of progression to AIDS in HIV-1 infection. Lancet 1992;339:1436-1440.
13. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL: Serum neopterin changes in HIV-1-infected subjects: Indicator of significant pathology, CD4 T cell changes and the development of AIDS. J Acquir Immune Defic Syndr 1989;2:70-76.
14. Godfried MH, van der Poll T, Weverling GJ, et al: Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-745.
15. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Detels R: Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels; results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS cohort study. J Acquir Immune Defic Syndr 1993;6:904-912.
16. Detels R, English PA, Giorgi JV, et al: Patterns of CD4+ cell changes after HIV-1 infection indicate the existence of a codeterminant of AIDS. J Acquir Immune Defic Syndr 1988;1: 390-395.
17. DeWolf F, Goudsmit J, Paul DA, et al: Risk of AIDS related complex and AIDS in homosexual men with persistent HIV-1 antigenemia. BMJ 1987;295:569-572.
18. Henrard ER, Phillips JF, Muenz LR, et al: Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-558.
19. Hogervorst E, Jurriaans S, de Wolf F, et al: Predictors for non- and slow progression in human immunodeficiency virus (HIV-1) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995;171:811-821.
20. Mellors JW, Kingsley LA, Rinaldo CR, et al: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579.
21. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
22. O'Brien TR, Blattner WA, Waters D, et al: Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 1996;276:105-110.
23. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D: HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-648.
24. Zangerle R, Fuchs D, Sarcletti M, et al: Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection. Clin Immunol Immunopathol 1994; 72:328-334.
25. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
26. Izopet J, Poggi C, Dussaix E, et al: Assessment of a standardized reverse-transcriptase PCR assay for quantifying HIV-1 RNA in plasma and serum. J Virol Methods 1996;60:119-129.
27. Zangerle R, Gallati H, Sarcletti M, Weiss G, Denz H, Wachter H, Fuchs D: Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-1 infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994;7:79-85.
28. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-534.
29. Dickover R, Herman S, Saddiq K, Wafer D, Bryson Y: Stability of HIV-1 RNA in whole blood stored at room temperature and effect of anticoagulant. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996.
30. Phillips AN, Lee CA, Elford J, et al: Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991;337:389-392.
31. DeGruttola V, Wulfsohn M, Fischl MA, Tsiatis A: Modelling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993;6:359-365.
32. Coombs RW, Welles SL, Hooper C, et al: Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-712.
33. Galetto-Lacour A, Yerly S, Perneger T, et al: Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis 1996;173:1388-1393.
34. Sacktor N, Liu X, Popescu M, Marder K, Stern Y, Mayeux R: Serum neopterin level predicts HIV-related mortality but not progression to AIDS or development of neurological disease in gay men and patenteral drug users. Arch Neurol 1995;52:676-679.
35. Blatt SP, McCarthy WF, Bucko-Krasnicka B, et al: Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons. J Infect Dis 1995;171:837-844.
36. Huber C, Batchelor JR, Fuchs D, et al: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-316.
37. Werner-Felmayer G, Werner ER, Fuchs D, Hauser A, Reibnegger G, Wachter H: Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989;370:1063-1069.
38. Gehr G, Gentz R, Brockhaus M, Lötscher H, Lesslauer W: Both tumor necrosis factor types mediate proliferative signals in human mononuclear cell activation. J Immunol 1992; 149:911-917.
39. Schobersberger W, Hoffmann G, Hobisch-Hagen P, et al: Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. FEBS Lett 1996;397: 263-268.
40. Kalinkovich A, Gelezjunas R, Kemper O, et al: Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection. J Interferon Cytokine Res 1995;15:749-757.
41. Lantz, M, Malik S, Slevin ML, Olsson I: Infusion of tumor necrosis factor TNF causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-406.
42. Fuchs D, Zangerle R, Artner-Dworzak E, et al: Association between immune activation, changes of iron metabolism and anemia in patients with human immunodeficiency virus (HIV) infection. Eur J Haematol 1993;50: 90-94.
43. Zangerle R, Reibnegger G, Wachter H, Fuchs D: Weight loss in HIV-1 infection is associated with immune activation. AIDS 1993;7:175-181.
44. Apolonio EG, Hoover DR, He Y, et al: Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count <50/μl. J Infect Dis 1995;171:829-836.
45. Colford JM, Ngo L. Tager I: Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. Am J Epidemiol 1994;139:206-218.
46. Giorgi JV: HIV pathogenesis and prognostic markers of HIV disease progression: Update from the Multicenter AIDS Cohort Study. 3rd Conference on Retroviruses and Opportunistic Infections: Washington, 1996.
47. Effros RB, Allsopp R, Chiu CP, et al: Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996; 10:F17-F22.
48. Fischl MA, Richman DD, Hansen N. et al: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV-1) infection: A double-Bind. placebo-controlled trial. Ann Intern Med 1990;112: 727-737.
49. Spijkerman IJB, Koot M, Prins M, et al: Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 1995;9:1085-1092.
50. Fernando Cruz E, Desco M, Montes MG, Longo N, Gonzalez B, Zabay JM: Immunological and serological markers predictive of progression to AIDS in a cohort of HIV infected drug users. AIDS 1990;4:987-994.
51. Munoz A, Vlahov D, Solomon L, et al: Prognostic indicators for development of AIDS among injecting drug users. J Acquir Immune Defic Syndr 1992;5:694-701.
52. Zangerle R, Fuchs D, Reibnegger G, Fritsch P, Wachter H: Markers for disease progression in injecting drug users infected with HIV-1. AIDS 1991;5:985-991.
53. Spijkerman IJB, Langendam MW, Veugelers PJ, et al: Differences in progression to AIDS between injecting drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996;7:571-577.
54. Hoover DR, Saah AJ, Bacellar H, et al: Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993;329: 1922-1926.